Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.46 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219553 | 0.96 | ADORA3 (0.49) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| Acetaldehyde SCHEMBL27678170 | 0.92 | ADORA3 (0.48) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| Phosphoric Acid SCHEMBL18486577 | 0.89 | ADORA1 (0.45) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL474415 | 0.87 | P2RY1 (0.56) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| Phosphoric Acid SCHEMBL9394402 | 0.87 | ADORA1 (0.44) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| Phosphoric Acid SCHEMBL20505441 | 0.87 | ADORA1 (0.44) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5742074 | 0.87 | EGFR (0.49) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29655156 | 0.86 | ADORA3 (0.50) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2463541 | 0.86 | ADORA3 (0.50) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28215296 | 0.85 | ADORA3 (0.49) | ADORA1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243168-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INST (US) | 2025-07-31 | — | — | US | disclosed |
| US-12281084-B2 | Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same | THE WISTAR INSTITUTE (US) | 2025-04-22 | — | — | US | disclosed |
| US-20220281826-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE | 2022-09-08 | — | — | US | disclosed |
| EP-3983391-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | The Wistar Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252407-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8518635-B2 | Regulation of protein activity by reversible acetylation | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2029731-B1 | REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION | DAVID GLADSTONE INST (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20090061015-A1 | Regulation of Protein Activity By Reversible Acetylation | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-03-05 | — | — | US | disclosed |
| EP-2029731-A2 | REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION | The J. David Gladstone Institutes (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007149270-A9 | REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION | DAVID GLADSTONE INST (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007149270-A2 | REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281084-B2 | Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same | ACSS2, ACACB, ACACA | DPP4 1824/4885ADRB2 4010/4885KCNH2 4706/4885 |
| US-20220281826-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | ACSS2, ACACB, ACACA | DPP4 1824/4885ADRB2 4010/4885KCNH2 4706/4885 |
| US-20250243168-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | ACSS2, ACACB, ACACA | DPP4 1824/4885ADRB2 4010/4885KCNH2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.